Nikunj Patel

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

N. Rokutanda, T. Okusaka, V. Breder, 2024, The Lancet. Oncology.